Understanding how a protein affects antibody development

The Role of UNG2 Degradation in Antibody Maturation

NIH-funded research Wayne State University · NIH-11097200

This study is looking at how a protein called mFAM72A helps improve the way our immune system makes antibodies, which are important for fighting off infections, and it could lead to better treatments for people with immune-related conditions.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionWayne State University NIH-funded
Lab location1 site (Detroit, United States)
Project IDNIH-11097200 on NIH RePORTER

What this research studies

This research investigates the role of a specific protein, mFAM72A, in the maturation of antibodies, which are crucial for the immune response. It focuses on how mFAM72A interacts with another protein, mUNG2, to regulate processes that enhance the effectiveness of antibodies. By examining the degradation of mUNG2, the research aims to uncover mechanisms that could improve antibody responses in patients. The study uses advanced molecular biology techniques to analyze these interactions in B lymphocytes, which are vital for producing antibodies.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals with conditions that affect antibody production or those who are immunocompromised.

Not a fit: Patients with stable immune function and no history of antibody-related disorders may not receive direct benefits from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved strategies for enhancing antibody responses, potentially benefiting patients with weakened immune systems or those undergoing treatments like chemotherapy.

How similar studies have performed: Other research has shown promising results in understanding antibody maturation processes, suggesting that this approach could yield valuable insights.

Where this research is happening

Detroit, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer Agents
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.